ERBB2 and breast cancer: Approximately 20–25% of breast cancer tumors are HER2+ and are now effectively treated with a combination of trastuzumab and pertuzumab added to standard chemotherapy [7,8], thereby transforming the treatment paradigm in this population of breast cancer.